Finding new molecules that enhance the effects of natural pain-relieving substances in the brain.
Identification of small molecules that regulate endogenous opioid signaling by inhibiting angiotensin converting enzyme
This study is looking for new tiny compounds that can help boost your body's natural pain relief by stopping a brain enzyme from breaking down a helpful peptide, which could lead to better ways to manage pain.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10886577 on NIH RePORTER |
What this research studies
This research focuses on discovering small molecules that can inhibit the angiotensin-converting enzyme (ACE) in the brain, which is known to degrade a specific pain-relieving peptide. By preventing this degradation, the study aims to enhance the signaling of endogenous opioids, potentially leading to better pain management. The researchers will test various compounds to identify those that effectively regulate this process in the nucleus accumbens, a key area of the brain involved in reward and pain. The approach combines biochemical assays and animal models to evaluate the efficacy of these new molecules.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic pain conditions who may benefit from enhanced opioid signaling.
Not a fit: Patients who do not experience pain or have conditions unrelated to opioid signaling may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for pain management that utilize the body's own opioid system, reducing reliance on external opioids.
How similar studies have performed: Other research has shown promise in using ACE inhibitors to modulate opioid signaling, suggesting that this approach could be effective.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: More, Swati S — University of Minnesota
- Study coordinator: More, Swati S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.